$410m Ambit deal bolsters Daiichi Sankyo's oncology presence
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo is to purchase US oncology-focused venture Ambit Biosciences for up to $410m, bringing the major Japanese firm an attractive Phase III asset for acute myeloid leukemia and boosting its oncology pipeline.
You may also be interested in...
Approval of Daiichi Sankyo’s Vanflyta Sets Up FLT3 Head-To-Head Competition
After over a decade in development, Vanflyta scored FDA approval in newly diagnosed FLT3-ITD acute myeloid leukemia, where Novartis FLT3 inhibitor Rydapt has been on the market for years.
Daiichi Sankyo Lays Out Priorities As It Pursues Oncology Ambitions
Daiichi Sankyo says it is “committed to a major transformation in oncology” as it prioritizes and pursues projects in this field under a new team leader, who chose to highlight unique antibody-drug conjugate technology and the acute myeloid leukemia franchise at a recent R&D Day in Tokyo.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.